Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma.

For KRAS A146T, the MAPK and the PI3K‐Akt signaling pathways were also enriched in cells carrying the mutation with an NES of 1.02 and 1.11, respectively; however, the enrichment did not reach statistical significance.

also in 111,027 other papers